Soleno wins FDA priority review for Prader-Willi therapy
The FDA also plans to hold an advisory committee for the DCCR therapy for Prader-Willi syndrome, with a PDUFA date of 27 December 2024.
The FDA also plans to hold an advisory committee for the DCCR therapy for Prader-Willi syndrome, with a PDUFA date of 27 December 2024.
What's Your Reaction?
